Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2023 Oct 24

PMID 37873633

Authors

Moon Seong Baek

Ae-Rin Baek

Sang-Bum Hong

Soohyun Bae

Hye Kyeong Park

Changhwan Kim

Hyun-Kyung Lee

Woo Hyun Cho

Jin Hyoung Kim

Youjin Chang

Heung Bum Lee

Hyun-Il Gil

Beomsu Shin

Kwang Ha Yoo

Jae Young Moon

Jee Youn Oh

Kyung Hoon Min

Kyeongman Jeon

Affiliations

Soon will be listed here.

Abstract

Background: There is insufficient data on the benefits of empiric antibiotic combinations for hospital-acquired pneumonia (HAP). We aimed to investigate whether empiric anti-pseudomonal combination therapy with fluoroquinolones decreases mortality in patients with HAP.

Methods: This multicenter, retrospective cohort study included adult patients admitted to 16 tertiary and general hospitals in Korea between January 1 and December 31, 2019. Patients with risk factors for combination therapy were divided into anti-pseudomonal non-carbapenem β-lactam monotherapy and fluoroquinolone combination therapy groups. Primary outcome was 30-day mortality. Propensity score matching (PSM) was used to reduce selection bias.

Results: In total, 631 patients with HAP were enrolled. Monotherapy was prescribed in 54.7% (n = 345) of the patients, and combination therapy was prescribed in 45.3% (n = 286). There was no significant difference in 30-day mortality between the two groups (16.8% vs. 18.2%, = 0.729) or even after the PSM (17.5% vs. 18.2%, = 0.913). After the PSM, adjusted hazard ratio for 30-day mortality from the combination therapy was 1.646 (95% confidence interval, 0.782-3.461; = 0.189) in the Cox proportional hazards model. Moreover, there was no significant difference in the appropriateness of initial empiric antibiotics between the two groups (55.0% vs. 56.8%, = 0.898). The proportion of multidrug-resistant (MDR) pathogens was high in both groups.

Conclusion: Empiric anti-pseudomonal fluoroquinolone combination therapy showed no survival benefit compared to β-lactam monotherapy in patients with HAP. Caution is needed regarding the routine combination of fluoroquinolones in the empiric treatment of HAP patients with a high risk of MDR.

References

Assefa M . Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia (Nathan). 2022; 14(1):4. PMC: 9069761. DOI: 10.1186/s41479-022-00096-z. View

Latibeaudiere R, Rosa R, Laowansiri P, Arheart K, Namias N, Munoz-Price L . Surveillance cultures growing carbapenem-Resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin Infect Dis. 2014; 60(3):415-22. DOI: 10.1093/cid/ciu847. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Vilella A, Seifert C . Timing and appropriateness of initial antibiotic therapy in newly presenting septic patients. Am J Emerg Med. 2013; 32(1):7-13. DOI: 10.1016/j.ajem.2013.09.008. View

Zaragoza R, Vidal-Cortes P, Aguilar G, Borges M, Diaz E, Ferrer R . Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020; 24(1):383. PMC: 7322703. DOI: 10.1186/s13054-020-03091-2. View

Chung D, Song J, Kim S, Thamlikitkul V, Huang S, Wang H . High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011; 184(12):1409-17. DOI: 10.1164/rccm.201102-0349OC. View

Mullish B, Williams H . infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018; 18(3):237-241. PMC: 6334067. DOI: 10.7861/clinmedicine.18-3-237. View

Kuula L, Backman J, Blom M . Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactions. Pharmacol Res Perspect. 2022; 10(2):e00931. PMC: 8848630. DOI: 10.1002/prp2.931. View

Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N . Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015; 19:63. PMC: 4358713. DOI: 10.1186/s13054-015-0795-y. View

10.

Merchant S, Proudfoot E, Quadri H, McElroy H, Wright W, Gupta A . Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis. J Glob Antimicrob Resist. 2018; 14:33-44. DOI: 10.1016/j.jgar.2018.02.005. View

11.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

12.

Neuhauser M, Weinstein R, Rydman R, Danziger L, Karam G, Quinn J . Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289(7):885-8. DOI: 10.1001/jama.289.7.885. View

13.

Mandell L, Niederman M . Aspiration Pneumonia. N Engl J Med. 2019; 380(7):651-663. DOI: 10.1056/NEJMra1714562. View

14.

Wenzler E, Goff D, Humphries R, Goldstein E . Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. Infect Dis Ther. 2017; 6(2):149-172. PMC: 5446362. DOI: 10.1007/s40121-017-0149-y. View

15.

Owens Jr R, Ambrose P . Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005; 41 Suppl 2:S144-57. DOI: 10.1086/428055. View

16.

Raman G, Avendano E, Berger S, Menon V . Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis. 2015; 15:395. PMC: 4589179. DOI: 10.1186/s12879-015-1123-5. View

17.

Xu E, Perez-Torres D, Fragkou P, Zahar J, Koulenti D . Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management. Microorganisms. 2021; 9(3). PMC: 8001201. DOI: 10.3390/microorganisms9030534. View

18.

Jiao J, Li Z, Wu X, Cao J, Liu G, Liu Y . Risk factors for 3-month mortality in bedridden patients with hospital-acquired pneumonia: A multicentre prospective study. PLoS One. 2021; 16(3):e0249198. PMC: 8009424. DOI: 10.1371/journal.pone.0249198. View

19.

Chang Y, Jeon K, Lee S, Cho Y, Kim Y, Chong Y . The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study. J Korean Med Sci. 2021; 36(41):e251. PMC: 8546312. DOI: 10.3346/jkms.2021.36.e251. View

20.

Kang J, Moon C, Mun S, Lee J, Lee S, Lee S . Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea. J Korean Med Sci. 2021; 36(43):e273. PMC: 8575761. DOI: 10.3346/jkms.2021.36.e273. View